Editas Medicine Inc

NASDAQ:EDIT

3.59

+0.10 (+2.86%)

7:55:39 PM EDT: $3.58 -0.01 (-0.28%)

Market Cap (Intraday)	304.56M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$4.51 Million
Adjusted EPS	-$0.78

See more estimates

10-Day MA	$3.67
50-Day MA	$4.58
200-Day MA	$6.89

See more pivots

Editas Medicine Inc Stock, NASDAQ:EDIT

11 Hurley Street, 11 Hurley Street, Cambridge, Massachusetts 02141

United States of America

Phone: +1.617.401.9000

Number of Employees: 265

http://www.editasmedicine.com

Description

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.